| DPP-4抑制剂用于治疗2型糖尿病合并非酒精性脂肪肝的新进展 |
| |
| 引用本文： | 王芬芬,张永莉.DPP-4抑制剂用于治疗2型糖尿病合并非酒精性脂肪肝的新进展[J].海南医学,2014(22):3361-3363. |
| |
| 作者姓名： | 王芬芬 张永莉 |
| |
| 作者单位： | 延安大学附属医院东关分院综合内科,陕西 延安,716000 |
| |
| 摘 要： | 二肽基肽酶Ⅳ抑制剂（DPP-4抑制剂）是一种新的糖尿病治疗药物,其能安全有效降糖,又能改善胰岛素抵抗,为2型糖尿病（T2DM）合并非酒精性脂肪肝（NAFLD）的转归提供一种新的可能,是近年研究的热点。本文就其在T2DM合并NAFLD治疗中可能的疗效和临床证据进行综述。
|
| 关 键 词： | DPP-4抑制剂 2型糖尿病 非酒精性脂肪肝 |
Progress in DPP-4 inhibitors for the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver |
| |
| WANG Fen-fen,ZHANG Yong-li.Progress in DPP-4 inhibitors for the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver[J].Hainan Medical Journal,2014(22):3361-3363. |
| |
| Authors: | WANG Fen-fen ZHANG Yong-li |
| |
| Institution: | .( Comprehensive Department, East Branch of Affiliated Hospital of Yan＇an University, Yan＇ an 716000, Shaanxi, CHINA) |
| |
| Abstract: | Dipeptidyl peptidase Ⅳ inhibitors（DPP-4 inhibitor） was a new oral drug for the treatment of diabetes, which not only decresed blood glucose safely and effectively, but also improved the insulin resistance and provided a new possibility for the outcome of type 2 diabetes mellitus（T2DM） patients with non-alcoholic fatty liver disease（NAFLD）. This article reviewed its efficacy and clinical evidence of T2 DM with NAFLD. |
| |
| Keywords: | DPP-4 inhibitors Type 2 diabetes mellitus non-alcoholic fatty liver disease |
| 本文献已被 维普 万方数据 等数据库收录！ |
